Nominating and Governance Committee Charter


(as amended on 9/23/16)

The purpose of the Nominating and Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Chimerix, Inc. (the “Company”) is to (i) oversee all aspects of the Company’s corporate governance functions on behalf of the Board; (ii) make recommendations to the Board regarding corporate governance issues; (iii) identify, review and evaluate candidates to serve as directors of the Company consistent with criteria approved by the Board and review and evaluate incumbent directors; (iv) serve as a focal point for communication between such candidates, non-committee directors and the Company’s management; (v) select or recommend to the Board for selection candidates to the Board to serve as nominees for director for the annual meeting of stockholders; and (vi) make other recommendations to the Board regarding affairs relating to the directors of the Company.

The policy of the Committee, in discharging these obligations, shall be to promote best corporate governance practices, ensure the Board is comprised of only highly qualified directors, and foster an open avenue of communication between the Committee and management of the Company.

The Committee shall consist of at least two members of the Board. No Committee member shall be an employee of the Company and each member shall be an independent director as determined by the Board, in accordance with the applicable independence requirements of The Nasdaq Stock Market (“Nasdaq”), when and as required by Nasdaq. The members of the Committee and the Committee chairperson shall be appointed by the Board.

The Committee shall hold such regular or special meetings as its members deem necessary or appropriate. The Chairman of the Committee will report to the Board from time to time, or whenever so requested by the Board.

The Committee shall have authority to retain and determine compensation for, at the expense of the Company, special legal, accounting or other advisors or consultants as it deems necessary or appropriate in the performance of its duties, including executive search firms to help identify director candidates. The Committee shall also have authority to pay, at the expense of the Company, ordinary administrative expenses that, as determined by the Committee, are necessary or appropriate in carrying out its duties. Each member of the Committee shall have full access to all books, records, facilities and personnel    of the Company as deemed necessary or appropriate by any member of the Committee to discharge his or her responsibilities hereunder.  The Committee shall have authority to require that any of the Company’s personnel, counsel, accountants             or investment bankers, or any other consultant or advisor to the Company attend any meeting of the Committee or meet       with any member of the Committee or any of its special outside legal, accounting or other advisors or consultants. The approval of this charter by the Board shall be construed as a delegation of authority to the Committee with respect to the responsibilities set forth herein.

The operation of the Committee will be subject to the provisions of the Bylaws of the Company and the Delaware General Corporation Law, each as in effect from time to time. The Committee will have the full power and authority to carry out the following primary responsibilities or to delegate such power and authority to one or more subcommittees of the Committee:

  • Director Nominations – The Committee shall have the responsibility of identifying, reviewing and evaluating candidates to serve on the Board, including consideration of any potential conflicts of interest as well as applicable independence and experience requirements. The Committee shall have primary responsibility for determining the minimum    qualifications for service on the Board and the right to modify the qualifications from time to time. The Committee shall also have the primary responsibility for reviewing, evaluating and considering the recommendation for nomination of incumbent directors for reelection to the Board, as well as monitoring the size of the Board. The Committee shall also select or recommend to the Board for selection candidates to the Board to serve as nominees for director for the annual meeting of stockholders. The Committee shall also have the power and authority to consider recommendations for Board nominees and proposals submitted by the Company’s stockholders and to establish any policies, requirements, criteria and procedures, including policies and procedures to facilitate stockholder communications with the Board, to recommend to the Board appropriate action on any such proposal or recommendation and to make any disclosures required by applicable law in the course of exercising its authority.
  • Board and Director Assessment – The Committee shall periodically review, discuss and assess the performance of  the Board, including Board committees, seeking input from senior management, the full Board and others. The assessment shall include evaluation of the Board’s contribution as a whole and effectiveness in serving the best interests of the Company and its stockholders, specific areas in which the Board and/or management believe contributions could be improved, and overall Board composition and makeup, including the reelection of current Board members. The factors to be considered shall include whether the directors, both individually and collectively, can and do provide the       integrity, experience, judgment, commitment (including having sufficient time to devote to the Company and level of participation), skills, diversity and expertise appropriate for the Company. In assessing the directors, both individually and collectively, the Committee may consider the current needs of the Board and the Company to maintain a balance of knowledge, experience and capability in various areas. The Committee shall also consider and assess the independence of directors, including whether a majority of the Board continue to be independent from management in both fact and appearance, as well as within the meaning prescribed by Nasdaq. The results of these reviews shall be provided to the Board for further discussion as appropriate.
  • Board Committee Nominations – The Committee, after due consideration of the interests, independence and experience of the individual directors and the independence and experience requirements of Nasdaq, the rules and regulations of the Securities and Exchange Commission and applicable law, shall evaluate the performance of the members of the committees of the Board, review the composition of such committees and recommend to the entire Board annually the chairmanship and membership of each such committee.
  • Board Meeting Procedures – assist the Board chair or lead director in developing effective Board meeting practices and procedures.
  • Corporate Governance Principles – The Committee shall develop, as appropriate, a set of corporate governance principles to be applicable to the Company, shall periodically review and assess these principles and their application, and shall recommend any changes deemed appropriate to the Board for its consideration.
  • Code of Business Conduct and Ethics – The Committee shall periodically review and assess the adequacy of the Company’s Code of Business Conduct and Ethics (the “Code”), recommend any proposed changes to the Board for its consideration, and consider any request by directors or executive officers of the Company for a waiver from the Code.
  • Management Succession – The Committee shall periodically review with the Chief Executive Officer of the Company the plans for succession to the offices of the Company’s Chief Executive Officer and other key executive officers and make recommendations to the Board with respect to the selection of appropriate individuals to succeed to these positions.
  • Self-Assessment – The Committee shall review, discuss and assess its own performance at least annually.
  • Annual Charter Review – The Committee shall periodically review and assess the adequacy of this charter, including the Committee’s role and responsibilities as outlined in this charter, and shall recommend any proposed changes to the Board for its consideration.

 


Committee Members

James Niedel, MD, PhD
James Niedel, MD, PhD

James Niedel joined the Chimerix Board in 2011.  Dr. Niedel is a Managing Director of New Leaf Venture Partners, a healthcare technology fund, where he focuses on biopharmaceutical investments.  He was one of the founders of New Leaf in 2005, having moved with the healthcare team from the Sprout Group, where he had been a venture partner since 2002.  Prior to joining the venture industry, Dr. Niedel was Chief Science and Technology Officer for GlaxoSmithKline and a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. Before joining the pharmaceutical industry, Dr. Niedel was Professor of Medicine and Chief of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. At Duke, he directed a basic research laboratory studying signal transduction, was an editor of J. Biological Chemistry, J. Immunology, Blood and J. Leukocyte Biology and was selected a Searle Scholar.  He received MD and PhD (Biochemistry) degrees from the University of Miami and is a Fellow of the Royal College of Physicians (London).

Martha J. Demski
Martha J. Demski

Martha Demski has served as one of our directors since 2005. Since August 2011, Ms. Demski has served as Senior Vice President and Chief Financial Officer of Ajinimoto Althea, Inc. (formerly Althea Technologies, Inc.), a fully-integrated contract development and manufacturing organization.  From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated. Ms. Demski currently serves on the board of directors and chairs the audit committee of Adamas Pharmaceuticals, Inc.  Ms. Demski also serves as a member of the board, chair of the audit committee and member of the compensation committee of Neothetics, Inc.  Additionally Ms. Demski has over 13 years of banking experience with Bank of America and U.S. Trust.  Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance.

Catherine L. Gilliss, PhD, RN, FAAN
Catherine L. Gilliss, PhD, RN, FAAN

Catherine L. Gilliss, PhD, RN, FAAN, currently serves as the Dean and Helene Fuld Health Trust Professor of Nursing at the Duke University School of Nursing and Vice Chancellor for Nursing Affairs at Duke University. Dr. Gilliss was appointed Dean in 2004, and under her leadership, Duke has become one of the top schools of nursing in the nation. While at Duke, Dr. Gilliss has presided over several transformative initiatives, including the approval and implementation of two new doctoral degree programs: the PhD in Nursing degree program and the Doctor of Nursing Practice program. Dr. Gilliss serves as co-director of the federally-funded Graduate Nurse Education Demonstration designed to increase the numbers of advanced practice nurses able to provide care to the growing Medicare population. Dr. Gilliss has also focused on translational science and innovative models of health care delivery, and serves as the Director of the Duke Translational Nursing Institute. From 1998 until 2004, she was a professor and the Dean at the Yale University School of Nursing. Dr. Gilliss has served as President of the National Organization for Nurse Practitioner Faculties and the American Academy of Nursing. She is a member of the North Carolina Institute of Medicine. Dr. Gilliss earned her Masters of Nursing from the Catholic University of America and her PhD from the University of California, San Francisco, where she also completed postdoctoral studies.